New head of CMC and Operations
03.08.2012 - Belgian Amakem NV appointed Maarten van Geffen as new head of CMC and Operations in mid-July.
Van Geffen brings nearly 25 years international management experience in pharmaceutical development to Amakem, a kinase platform company focusing on ophthalmology. Previously, he was Director of Product Development at Shire-Movetis NV and responsible for the pharmaceutical development of the GI early and late phase products and was the CMC (Chemistry, Manufacturing & Controls) lead for due diligence of early phase and late phase small and large molecule products. Prior to working at Shire-Movetis NV, van Geffen held several positions as Director of CMC Regulatory Affairs at Barrier Therapeutic NV, Centocor BV, and Janssen Research Foundation.http://www.european-biotechnology-news.com/people/bio-people/2012-2/maarten-van-geffen.html